Agenus Inc. (AGEN)
AGEN Stock Price Chart
Explore Agenus Inc. interactive price chart. Choose custom timeframes to analyze AGEN price movements and trends.
AGEN Company Profile
Discover essential business fundamentals and corporate details for Agenus Inc. (AGEN) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
8 Feb 2000
Employees
316.00
Website
https://www.agenusbio.comCEO
Garo H. Armen
Description
Agenus Inc., a clinical-stage immuno-oncology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops vaccine programs comprising Prophage vaccine candidate; and QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, an anti-PD-1 antagonist that has completed Phase II clinical trial to treat second line cervical cancer; AGEN1181, an anti-CTLA-4 monospecific antibody that is in Phase 1/2 clinical trial; AGEN2373, an anti-CD137 monospecific antibody that is in Phase 1 clinical trial; AGEN1423, a tumor microenvironment conditioning anti-CD73/TGFß TRAP bi-functional antibody that has completed Phase 1 clinical trial; AGEN1777, an anti-TIGIT bispecific antibodies; and AGEN1327, a human monoclonal antibody. In addition, the company develops INCAGN1876, an anti-GITR monospecific antibody; INCAGN1949, an anti-OX40 monospecific antibody; INCAGN2390, an anti-TIM-3 monospecific antibody; INCAGN2385, an anti-LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4; AGENT 797, an iNKT cells that is in Phase 1 clinical trial for solid tumors, multiple myeloma, and viral ARDS, as well as in clinical stage to treat hematological malignancies and multiple myeloma/B cells; and AGEN1884, a first-generation anti-CTLA-4 monospecific antibody. Agenus Inc. operates under ASV, Agenus, AutoSynVax, EVAMPLIX, MiNK, PSV, PhosPhoSynVax, Prophage, Retrocyte Display, and Stimulon trademarks. It has collaborations with Incyte Corporation, Merck Sharpe & Dohme, Recepta Biopharma SA, and Gilead Sciences, Inc. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.
AGEN Financial Timeline
Browse a chronological timeline of Agenus Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 11 May 2026
Upcoming earnings on 11 Nov 2025
EPS estimate is $2.63, while revenue estimate is $80.39M.
Earnings released on 11 Aug 2025
EPS came in at -$1.00 falling short of the estimated -$0.78 by -28.21%, while revenue for the quarter reached $25.69M , beating expectations by +2.85%.
Earnings released on 12 May 2025
EPS came in at -$1.03 surpassing the estimated -$1.61 by +36.02%, while revenue for the quarter reached $24.07M , beating expectations by +8.94%.
Earnings released on 11 Mar 2025
EPS came in at -$2.04 surpassing the estimated -$2.36 by +13.56%, while revenue for the quarter reached $26.84M , missing expectations by -10.82%.
Earnings released on 12 Nov 2024
EPS came in at -$3.17 falling short of the estimated -$2.10 by -50.95%, while revenue for the quarter reached $25.11M , missing expectations by -21.06%.
Earnings released on 8 Aug 2024
EPS came in at -$2.52 falling short of the estimated -$1.33 by -89.47%, while revenue for the quarter reached $23.51M , missing expectations by -61.76%.
Earnings released on 7 May 2024
EPS came in at -$3.04 surpassing the estimated -$3.58 by +15.08%, while revenue for the quarter reached $28.01M , missing expectations by -28.69%.
Stock split effective on 12 Apr 2024
Shares were split 1 : 20 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 14 Mar 2024
EPS came in at -$2.60 falling short of the estimated -$0.40 by -550.00%, while revenue for the quarter reached $83.80M , beating expectations by +78.11%.
Earnings released on 7 Nov 2023
EPS came in at -$3.20 surpassing the estimated -$3.80 by +15.79%, while revenue for the quarter reached $24.31M , missing expectations by -48.32%.
Earnings released on 8 Aug 2023
EPS came in at -$4.00 matching the estimated -$4.00, while revenue for the quarter reached $25.30M , beating expectations by +4.88%.
Earnings released on 9 May 2023
EPS came in at -$4.40 falling short of the estimated -$4.20 by -4.76%, while revenue for the quarter reached $22.90M , missing expectations by -0.34%.
Stock split effective on 26 Apr 2023
Shares were split 1019 : 1000 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 14 Mar 2023
EPS came in at -$4.80 falling short of the estimated -$4.40 by -9.09%, while revenue for the quarter reached $28.39M , beating expectations by +59.20%.
Earnings released on 8 Nov 2022
EPS came in at -$3.80 falling short of the estimated -$3.60 by -5.56%, while revenue for the quarter reached $22.77M , beating expectations by +10.05%.
Earnings released on 9 Aug 2022
EPS came in at -$3.40 surpassing the estimated -$4.60 by +26.09%, while revenue for the quarter reached $20.93M , beating expectations by +11.93%.
Earnings released on 10 May 2022
EPS came in at -$3.80 surpassing the estimated -$5.80 by +34.48%, while revenue for the quarter reached $25.94M , beating expectations by +119.82%.
Earnings released on 1 Mar 2022
EPS came in at -$5.20 falling short of the estimated -$3.20 by -62.50%, while revenue for the quarter reached $20.26M , missing expectations by -46.31%.
Earnings released on 9 Nov 2021
EPS came in at $13.80 surpassing the estimated $9.20 by +50.00%, while revenue for the quarter reached $252.95M , beating expectations by +38.14%.
Earnings released on 9 Aug 2021
EPS came in at -$7.40 falling short of the estimated -$4.80 by -54.17%, while revenue for the quarter reached $10.73M , meeting expectations.
Earnings released on 6 May 2021
EPS came in at -$5.40 surpassing the estimated -$6.20 by +12.90%, while revenue for the quarter reached $11.72M , missing expectations by -11.43%.
Earnings released on 15 Mar 2021
EPS came in at -$4.00 surpassing the estimated -$4.40 by +9.09%, while revenue for the quarter reached $31.26M , beating expectations by +127.00%.
Earnings released on 29 Oct 2020
EPS came in at -$5.60 falling short of the estimated -$5.20 by -7.69%, while revenue for the quarter reached $14.83M .
AGEN Stock Performance
Access detailed AGEN performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.